(Q36511295)

14 August 2017

1 reference

title

Biomarkers in Parkinson's disease (English)

1 reference

14 August 2017

0 references

1 reference

E Ray Dorsey

1

1 reference

14 August 2017

Robert G Holloway

series ordinal

2

1 reference

14 August 2017

Bernard M Ravina

series ordinal

3

1 reference

14 August 2017

publication date

1 June 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

14 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

823-831

1 reference

Levodopa and the progression of Parkinson's disease

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Clinical practice. Diagnosis and initial management of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

How valid is the clinical diagnosis of Parkinson's disease in the community?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Biomarkers and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Abnormal performance on the PD test battery by asymptomatic first-degree relatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Parkinsonian voice acoustic analysis in real-time after stereotactic thalamotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Square wave jerks in parkinsonian syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Deficits in saccadic eye-movement control in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Quantification of motor deficit in Parkinson's disease with a motor performance test series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Idiopathic hyposmia as a preclinical sign of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Neuroimaging trials of Parkinson's disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

(123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Relationship of substantia nigra echogenicity and motor function in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Parkinson disease in twins: an etiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Nosology of Parkinson's disease: looking for the way out of a quagmire

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Genetics of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

Prevalence of Parkinson's disease in the elderly: The Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

LRRK2G2019S as a Cause of Parkinson's Disease in North African Arabs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.823

21 January 2018

Identifiers

DOI

10.1586/14737175.6.6.823

1 reference

14 August 2017

1 reference